Nivolumab
- CAS No.
- 946414-94-4
- Chemical Name:
- Nivolumab
- Synonyms
- Opdivo;ONO 4538;MDX 1106;Nivolumab;BMS 936558;Nivolumab 10mg/ml;Nivolumab USP/EP/BP;Nivolumab (anti-PD-1);Research Grade Nivolumab(DHH02209)
- CBNumber:
- CB42738187
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2024/7/2 8:55:08
Nivolumab Chemical Properties,Uses,Production
Mechanism of action
Nivolumab is a fully human, monoclonal IgG4 antibody that binds to programmed death-1 (PD-1) receptors with high specificity and affinity. PD-1 is expressed on T cells and dampens their immune response upon binding ligands PD-L1 and PD-L2 on APCs. This mechanism is pivotal to regulating central and peripheral tolerance. In cancer, aberrant PD-L1 expression by tumor cells or immune cells in the tumor microenvironment deactivates PD-1, expressing tumor-infiltrating lymphocytes, thereby allowing tumor cells to escape immune recognition and elimination. By inhibiting PD-1 function, nivolumab releases immune cells from pathological immune suppression, allowing them to recognize and counter tumor cells.
Side effects
The most common Immune-related adverse events (iRAEs) affect systems include the gastrointestinal and integumentary systems, usually manifesting as a pruritic rash, diarrhea, or colitis. When immune-mediated endocrine inflammation subdues, glandular function may be compromised, thus necessitating permanent hormone substitution. This includes nivolumab-induced hypothyroidism, hypopituitarism, adrenal insufficiency, and diabetes mellitus type 1.
Immune-mediated pneumonitis is a rare adverse effect associated with severe manifestations. Immune-related myocarditis is a very uncommon adverse event with high lethality. Less common adverse effects include ocular (uveitis, conjunctivitis, myositis of periocular muscles), inflammatory hepatitis, endocrinopathies such as hypothyroidism, hypopituitarism, and adrenal insufficiency. Other rare adverse events include those affecting the neurological system (encephalitis, Guillain-Barré syndrome).
References
[1] Anthony V Serritella, Niraj K Shenoy. “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.” Jama Oncology (2023): 1441–1446.
[2] Jonathan Ho, C. Kelly, Erick A. Argueta. “S3644 Nivolumab-Induced Liver Injury.” American Journal of Gastroenterology (2021).
[3] Yang Wang. “Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.” Anti-Cancer Drugs (2024).
Nivolumab Preparation Products And Raw materials
Raw materials
Preparation Products
Nivolumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | CHINA | 129 | 58 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29825 | 58 | Inquiry |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | China | 10326 | 58 | Inquiry |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | China | 24330 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Wuhan Fortuna Chemical Co., Ltd | +86-027-59207850 | China | 5989 | 58 | Inquiry |
| Baoji Guokang Healthchem co.,ltd | +8615604608665 15604608665 | CHINA | 9427 | 58 | Inquiry |
| InvivoChem | +1-708-310-1919 +1-13798911105 | United States | 6393 | 58 | Inquiry |
| LEAP CHEM CO., LTD. | +86-852-30606658 | China | 24738 | 58 | Inquiry |
946414-94-4(Nivolumab)Related Search:
1of4
chevron_right